Stay updated on Pembrolizumab SubQ vs IV in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check24 days agoChange DetectedThe date for results has been updated from December 18, 2023, to February 10, 2025, indicating a significant delay in the timeline for results posting.SummaryDifference1%
- Check31 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference6%
- Check39 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check53 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check60 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference1.0%
Stay in the know with updates to Pembrolizumab SubQ vs IV in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page.